Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
VPC 23019Cat. No. 4195 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 2-Amino-N-(3-octylphenyl)-3-(phosphonooxy)-propanamaide |
Biological Activity
Sphingosine-1-phosphate receptor antagonist; inhibits S1P1 and S1P3 receptors (pKi values are 7.86 and 5.93 respectively).Certificate of Analysis / Safety Data Sheet
References
Davis et al (2005) Sphingosine-1-phosphate analogs as receptor antagonists. J.Biol.Chem. 280 9833. PMID: 15590668.
Aoki et al (2007) The suppressive effect of sphingosine-1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins α5β1 and αVβ3. J.Thromb.Haemost. 5 1292. PMID: 17403093.
Mihovilovic et al (2007) High-fat/cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL. J.Lipid Res. 48 806. PMID: 17264352.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: VPC 23019, supplier, VPC23019, sphingosine-1-phosphate, s1p1, s1p3, antagonists, s1p, sphingolipids
Quick Order
Find multiple products by catalog number
Cardiovascular Guide
Request your free copy
Highlights over 250 products for cardiovascular research. Request a copy or view PDF today.
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
VEGF Pathway & Anti-Angiogenic Therapy
Written by N. Ferrara & Y. Crawford
A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.
New Products in this Area
Potent and selective S1P4 agonist
H2L5186303Potent and selective LPA2 receptor antagonist
MEDICA 16FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
BX 471Potent, selective CCR1 antagonist
PF 04418948Potent and selective EP2 receptor antagonist
LatanoprostFP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
GRI 977143Selective LPA2 receptor non-lipid agonist
CYM 50260Potent and selective S1P4 agonist
G-36Selective GPR30 antagonist
Strontium chlorideCalcium sensing receptor (CaSR) agonist
CS 2100Selective S1P1 agonist
SMANT hydrochlorideInhibits Smoothened (Smo) accumulation
TUG 891Potent and selective GPR120 agonist
IT1t dihydrochloridePotent CXCR4 antagonist
RuBi GABA trimethylphosphineCaged GABA; inhibits neural activity
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.